Sugi Predict

Sugi Predict / Compounds / SCHEMBL3436829

SCHEMBL3436829

SCHEMBL3436829

CC1(C)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ HPGD P15428 1/20 0.47
▸ EPHX2 P34913 1/20 0.46
▸ RECQL P46063 1/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TSHR P16473 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ GPR119 Q8TDV5 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12696568 0.93 HPGD (0.50) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL4210880 0.90 USP2 (0.50) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL78071 0.86 USP2 (0.55) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL24167747 0.86 USP2 (0.44) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL18014676 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL182080 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL25723152 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL13232132 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL18563357 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL
SCHEMBL15770602 0.85 USP2 (0.53) USP2SMN1; SMN2HPGDEPHX2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332156-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-10-30 — — US disclosed
US-20250312504-A1 VOLATILE COMPOSITION DISPENSER FOR COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE THE PROCTER & GAMBLE COMPANY 2025-10-09 — — US disclosed
CN-112368641-B Photosensitive resin composition, photosensitive sheet, cured film thereof, method for producing cured film, and electronic component 东丽株式会社 2025-05-02 — — CN disclosed
CN-119546575-A Pharmaceutical compositions comprising WRN helicase inhibitors 维维迪恩医疗公司 2025-02-28 — — CN disclosed
WO-2024182447-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K VIVIDION THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024133730-A1 CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER STEP PHARMA S.A.S. (FR) 2024-06-27 — — WO disclosed
US-20240199997-A1 COMPOSITIONS COMPRISING A META-(C1-C4 ALKOXY) SALICYLALDEHYDE PROCTER & GAMBLE COMPANY, THE 2024-06-20 — — US disclosed
WO-2024010784-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
WO-2023166076-A1 COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER STEP PHARMA S.A.S. (FR) 2023-09-07 — — WO disclosed
US-20230272002-A1 PHOTOREDOX PROTEIN MODIFICATION THE ROSALIND FRANKLIN INSTITUTE (GB) 2023-08-31 — — US disclosed
US-20110178112-A1 PPAR Modulators EVOLVA SA (CH) 2011-07-21 — — US disclosed
US-20110166122-A1 SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2011-07-07 — — US disclosed
US-20100247514-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2010-09-30 — — US disclosed
US-20100168169-A1 SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS EVOLVA SA (CH) 2010-07-01 — — US disclosed
US-20100168169-A1 SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS EVOLVA SA (CH) 2010-07-01 — — US disclosed
WO-2010048314-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-04-29 — — WO disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-11-19 — — US disclosed
EP-2009005-A1 AZOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-12-31 — — EP disclosed
WO-2004043916-A1 PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332156-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN USP2 1283/4885SMN1; SMN2 664/4885HPGD 654/4885
US-20230272002-A1 PHOTOREDOX PROTEIN MODIFICATION PPOX, CACYBP, BRI3BP USP2 906/4885SMN1; SMN2 4320/4885HPGD 3027/4885
US-20110178112-A1 PPAR Modulators PPARD, PPARG, PPARA USP2 3461/4885SMN1; SMN2 1784/4885HPGD 575/4885
US-20100247514-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 USP2 662/4885SMN1; SMN2 470/4885HPGD 2941/4885
US-20110166122-A1 SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINE COMPOUNDS AS TRK KINASE INHIBITORS NTRK1, NTRK3, NTRK2 USP2 3593/4885SMN1; SMN2 844/4885HPGD 4126/4885
US-20100168169-A1 SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS PPARD, PPARG, PPARA USP2 3888/4885SMN1; SMN2 2207/4885HPGD 549/4885
US-20090286766-A1 AZOLECARBOXAMIDE DERIVATIVE GPR17, NTRK1, TRPV1 USP2 1496/4885SMN1; SMN2 3601/4885HPGD 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.